Per Sontum - Exact Therapeutics Founder
| EXTX Stock | NOK 5.70 0.10 1.72% |
Founder
Per Sontum is Founder of Exact Therapeutics AS
| Web | https://www.exact-tx.com |
Exact Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.256) % which means that it has lost $0.256 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4619) %, meaning that it generated substantial loss on money invested by shareholders. Exact Therapeutics' management efficiency ratios could be used to measure how well Exact Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. EXACT Therapeutics AS, a clinical stage biotech company, develops a technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy . The company was founded in 2012 and is based in Oslo, Norway. EXACT THERAPEUTICS is traded on Oslo Stock Exchange in Norway. Exact Therapeutics AS (EXTX) is traded on Oslo Stock Exchange in Norway and employs 8 people.Management Performance
| Return On Equity | -0.46 | |||
| Return On Asset | -0.26 |
Exact Therapeutics Leadership Team
Elected by the shareholders, the Exact Therapeutics' board of directors comprises two types of representatives: Exact Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Exact. The board's role is to monitor Exact Therapeutics' management team and ensure that shareholders' interests are well served. Exact Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Exact Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Per Walday, Chief Officer | ||
| Dominic Aca, Chief Officer | ||
| John Edminson, Chief Officer | ||
| Amir MD, Chief Officer | ||
| Hilary MD, Chief Officer | ||
| Svein Kvle, Co COO | ||
| Ragnar Bendicksen, VP Technology | ||
| Masha DPHIL, ViceChair Board | ||
| Andrew Healey, Co Officer | ||
| Per Sontum, Founder |
Exact Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Exact Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.46 | |||
| Return On Asset | -0.26 | |||
| Operating Margin | (844.98) % | |||
| Current Valuation | 432.68 M | |||
| Shares Outstanding | 30 M | |||
| Shares Owned By Insiders | 64.13 % | |||
| Shares Owned By Institutions | 26.24 % | |||
| Price To Book | 6.55 X | |||
| Price To Sales | 8,803 X | |||
| Gross Profit | 52 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Exact Stock
Exact Therapeutics financial ratios help investors to determine whether Exact Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Exact with respect to the benefits of owning Exact Therapeutics security.